OncLive Staff

The final analysis of the Italian FIL-MOGA study showed an objective response lasting at least 4 months in 47% of patients and identified the measure as a surrogate for survival outcomes.

Distinct somatic mutation profiles separated responders from non-responders to mogamulizumab in mycosis fungoides and Sézary syndrome.

Daratumumab-based retreatment remained active in a broadly inclusive, transplant-ineligible newly diagnosed multiple myeloma population.

An off-the-shelf BCMA-directed CAR T-cell therapy generated a 100% overall response rate and universal MRD negativity in heavily pretreated myeloma.

Maintenance with chidamide and azacitidine generated high 3-year overall survival and a low relapse incidence in high-risk AML after allogeneic transplant.

In a phase 2 study, adding venetoclax to ibrutinib rendered BTK C481X resistance mutations undetectable in patients with CLL.

Both the reactive and proactive ibrutinib dose-adjustment cohorts of the phase 2 TAILOR study met the primary ORR end point in previously untreated CLL.

The top 5 OncLive TV videos of the week cover insights in renal cell carcinoma, HER2+ breast cancer, multiple myeloma, and chronic lymphocytic leukemia.

Six-year GARNET data show durable responses with dostarlimab in dMMR/MSI-H endometrial cancer.

The FDA accepted for review a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in LBCL, a BLA for ozekibart in chondrosarcoma, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The CDK4/6 inhibitor and aromatase inhibitor combination produced a 32% ORR and 48% clinical benefit rate at 6 months.

Updated data from the phase 2 COLIBRI-1 trial suggest that immune microenvironment status at baseline and following ICB induction may predict long-term survival.

Trastuzumab pamirtecan produced durable responses and encouraging survival in HER2-expressing endometrial cancer after prior therapy.

Emi-Le generated durable responses and encouraging PFS with manageable safety in patients with aggressive adenoid cystic carcinoma.

Zanubrutinib yielded sustained progression-free survival and a tolerable safety profile in older patients with CLL/SLL treated in the SEQUOIA trial.

Real-world data show liso-cel drives high response rates and durable benefit in relapsed/refractory MCL, including high-risk patients.

Rocbrutinib delivered durable responses and encouraging survival with manageable safety in BTK inhibitor–pretreated relapsed/refractory MCL.

Tuspetinib/venetoclax/azacitidine produced high CR and MRD-negativity rates across molecular subgroups of older or unfit patients newly diagnosed AML.

The first-in-class BTK degrader tacabrutideg produced an ORR of 94.1% at the recommended phase 2 dose in relapsed/refractory CLL/SLL.

Obe-cel delivered durable remissions in relapsed/refractory B-ALL, with the best efficacy and safety seen in patients with low disease burden.

Phase 1 data showed that INCA033989 produced rapid and durable responses as monotherapy and in a combination regimen in CALR-mutated myelofibrosis.

The type II JAK2 inhibitor AJ1-11095 produced SVRs, deep symptom responses, and mutation VAF reductions in type I JAK inhibitor–exposed myelofibrosis.

Luspatercept produced clinically meaningful improvements in RBC transfusion independence in myelofibrosis-associated anemia.

A phase 2 study of dose-adjusted EPOCH plus tafasitamab with or without rituximab met its primary end point of MRD negativity after the first cycle.

Fixed-duration venetoclax/obinutuzumab more than doubled median PFS vs chlorambucil/obinutuzumab in previously untreated CLL.

In the MAXILUS primary analysis, luspatercept initiated at 1.75 mg/kg yielded high RBC transfusion independence rates in lower-risk MDS.

Partial response to bridging therapy before cilta-cel was associated with improved PFS and OS outcomes in relapsed/refractory multiple myeloma.

Ficerafusp alfa plus pembrolizumab generated a 54% ORR and 21.7-month median DOR in first-line HPV-negative recurrent or metastatic HNSCC.

EPCORE FL-1 showed that epcoritamab/lenalidomide/rituximab yielded superior efficacy vs lenalidomide/rituximab across follicular lymphoma populations.